Price: quote on request. Your total cost is quoted in writing per case.
We reply within one business dayGet my quote

Keytruda vs Pemrydi RTU: how two US-approved medicines are used together in non-small cell lung cancer

Creator: Reserve Meds
Published: 2026-10-17

A side-by-side guide for families in the Gulf, built from the US FDA labels, Gulf drug registers and official sources.

Reviewed by the Reserve Meds clinical operations team on 17 October 2026. Facts on this page come from the current US prescribing information for each medicine.

Keytruda vs Pemrydi RTU: the short answer

Keytruda and Pemrydi RTU are not rivals. For first-line metastatic nonsquamous NSCLC without EGFR or ALK changes, both US labels describe giving them together with platinum chemotherapy. Your oncologist decides the plan. Reserve Meds is a digital health company. We do not diagnose or prescribe.

Condition: non-small cell lung cancer.
Main difference: These are not alternatives.
Head-to-head evidence: none; the shared trial tested the combination.
Price: Quote on request.

Keytruda and Pemrydi RTU side by side

The table summarizes each current US label. Labels are long; your specialist and hospital pharmacy work from the full text.

Feature	Keytruda	Pemrydi RTU
Generic name	pembrolizumab^[3]	pemetrexed^[4]
Type of medicine	PD-1 blocking antibody (immunotherapy)^[3]	chemotherapy (folate analog metabolic inhibitor) supplied as a solution that is infused without further dilution^[4]
US-approved for	For lung cancer on this page: with pemetrexed and platinum chemotherapy, first-line treatment of metastatic nonsquamous non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations. Keytruda has many other approved uses.^[3]	For lung cancer: nonsquamous non-small cell lung cancer, including first-line treatment of metastatic disease with pembrolizumab and platinum chemotherapy (no EGFR or ALK aberrations), with cisplatin, as maintenance, or alone after prior chemotherapy. It is not indicated for squamous NSCLC. It is also approved for mesothelioma.^[4]
First US approval (year on the label)	2014^[3]	2004^[4]
How it is given	Intravenous infusion over 30 minutes, 200 mg every 3 weeks or 400 mg every 6 weeks.^[3]	Intravenous infusion over 10 minutes, 500 mg/m2 on day 1 of each 21-day cycle, given undiluted. With pembrolizumab, it is given after pembrolizumab and before the platinum drug.^[4]
Where and what to expect	Liver enzymes, creatinine and thyroid function are checked at baseline and periodically.^[3]	Folic acid by mouth starts 7 days before the first dose, vitamin B12 injections are given every 3 cycles, and dexamethasone is taken around each dose. It is not given when creatinine clearance is below 45 mL/min.^[4]
Boxed warning	No boxed warning. Warnings: immune-mediated reactions that can affect any organ (lungs, bowel, liver, hormone glands, kidneys, skin), infusion reactions, and complications of stem cell transplant.^[3]	No boxed warning. Warnings: bone marrow suppression, kidney failure, severe skin reactions, lung inflammation (pneumonitis), radiation recall and harm to an unborn baby. Contraindicated after a severe allergic reaction to pemetrexed.^[4]

About non-small cell lung cancer and these two medicines

Lung cancer forms in tissues of the lung, usually in the cells that line the air passages. There are two main types, small cell and non-small cell lung cancer, and non-small cell lung cancer is the more common type.^[1]

Treatment depends partly on whether the cancer has changes in certain genes, such as EGFR or ALK. Your doctor may suggest biomarker tests to help predict the response to certain targeted therapy drugs.^[2]

The main difference

These are not alternatives. Keytruda is an immunotherapy and Pemrydi RTU is a solution of the chemotherapy pemetrexed that is given without further dilution. For first-line metastatic nonsquamous NSCLC without EGFR or ALK changes, both labels describe giving them together with platinum chemotherapy, on the same day, Keytruda first.^{[3, 4]}

The evidence behind each approval

Keytruda. KEYNOTE-189 was a randomized, double-blind trial in 616 patients with untreated metastatic nonsquamous NSCLC without EGFR or ALK changes. Keytruda plus pemetrexed and platinum chemotherapy was compared with placebo plus the same chemotherapy, and the label reports a statistically significant improvement in overall survival and progression-free survival.^[3]

Pemrydi RTU. The Pemrydi RTU label describes the same pemetrexed trials, including KEYNOTE-189. Pemrydi RTU itself was approved on 22 May 2023 (Drugs@FDA, NDA 215179). Pemetrexed was first approved in the US in 2004.^{[4, 5]}

One trial, two medicines. KEYNOTE-189 appears in both labels because it tested Keytruda added to pemetrexed and platinum chemotherapy. It does not compare Keytruda with pemetrexed; it shows the combination against chemotherapy alone.

How the two are used together

In KEYNOTE-189, Keytruda, pemetrexed and cisplatin or carboplatin were given on day 1 of each 21-day cycle for 4 cycles, then Keytruda and pemetrexed continued every 3 weeks. Pemrydi RTU is one pemetrexed product; the hospital may use another pemetrexed brand that is registered locally.^{[3, 4]}

Safety: what the labels warn about

Both labels list warnings that the treating team monitors. The boxed warning row in the table above is the most serious level of warning on a US label.

Keytruda: common side effects listed on the label include fatigue, musculoskeletal pain, rash, diarrhea, fever, cough and decreased appetite (when used alone).^[3]
Pemrydi RTU: common side effects listed on the label include fatigue, nausea and loss of appetite (when used alone).^[4]

Availability in the Gulf

Keytruda: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.^{[6, 7]}
Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, Egypt, Jordan, Iraq
Pemrydi RTU: Pemrydi RTU was not found by brand name in the SFDA drugs list or the Abu Dhabi DoH drug code list, but other pemetrexed products are listed in both. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.^{[6, 7]}
Country guides: Kuwait, Qatar, Bahrain, Jordan

How families in the Gulf can access Keytruda or Pemrydi RTU

If the medicine is listed in your country. Ask your specialist and the hospital pharmacy about local supply first. A listing does not mean every hospital stocks it, but local supply is usually the fastest route and you may not need us.

If it is not registered. The usual legal route is a named-patient request: the treating hospital, on your specialist's written request, asks the national regulator for permission to import the medicine for one patient, using the US FDA approval as the reference. In Saudi Arabia the SFDA Special Access Program guidance covers these requests; in Bahrain, NHRA Circular 41 of 2020 sets the procedure. Other Gulf countries have their own procedures, which the hospital pharmacy confirms.^{[8, 9]} Once approval is in place, Reserve Meds arranges supply through a US-licensed pharmaceutical wholesale partner to the hospital pharmacy.

We give you a written timeline estimate once we see the hospital file. The regulator, the treatment center and the manufacturer set their own timelines.

What treatment costs

Quote on request. Your total cost depends on the medicine, the dose, shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

How Reserve Meds helps

Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help your doctor and hospital prepare the file, arrange US supply and temperature-controlled shipping once approval is in place, and keep your family updated. We coordinate access to FDA-approved medicines only and we do not choose between medicines.

Ask us about Keytruda or Pemrydi RTU

Tell us the medicine, your country and a WhatsApp or phone number. We reply within one business day. On WhatsApp we usually reply the same day.

Frequently asked questions

Do I need Keytruda or Pemrydi RTU?

For first-line metastatic nonsquamous NSCLC without EGFR or ALK changes, the US labels describe using both together with platinum chemotherapy. Your oncologist decides whether this plan fits.

What is the main difference between Keytruda and Pemrydi RTU?

Are Keytruda and Pemrydi RTU available in Saudi Arabia or the UAE?

Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register. Pemrydi RTU was not found by brand name in the SFDA drugs list or the Abu Dhabi DoH drug code list, but other pemetrexed products are listed in both.

How can a family in the Gulf get Keytruda or Pemrydi RTU?

Ask the treating hospital about local supply first. If the medicine is not registered, the hospital can file a named-patient import request with the national regulator on your specialist's written request. Once approved, we arrange US supply to the hospital pharmacy.

How much do these medicines cost?

Quote on request. Your total cost, including the medicine, shipping, import steps and coordination, is quoted in writing for your case before you commit. No hidden charges.

Does Reserve Meds choose the medicine?

No. Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We do not diagnose, prescribe or choose between medicines. Your specialist and hospital make the medical decisions.

Sources

Checked on 17 October 2026. Labels, registers and regulator rules change. Your hospital pharmacy confirms the current position before filing.

This page is general health information, not medical advice. It does not replace a consultation with your doctor.